Compounds > 5-(2-chloroethyl)-2'-deoxyuridine
Page last updated: 2024-12-08

5-(2-chloroethyl)-2'-deoxyuridine

Description

5-(2-chloroethyl)-2'-deoxyuridine: inhibitor of herpes viruses; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID514814
CHEMBL ID2079575
CHEBI ID195580
SCHEMBL ID1627089
MeSH IDM0136850

Synonyms (20)

Synonym
5-(2-chloroethyl)-6-hydroxy-3-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-hydropyrimidin-2-one
90301-59-0
cedu
5-(2-chloroethyl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
brn 5976898
5-(2-chloroethyl)-2'-deoxyuridine
uridine, 5-(2-chloroethyl)-2'-deoxy-
2'-deoxy-5-(2-chloroethyl)uridine
ccris 2828
5-(2-chloroethyl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
CHEBI:195580
CHEMBL2079575
unii-h1sz5qc7qd
h1sz5qc7qd ,
SCHEMBL1627089
AKOS030239862
UUSHUCRHZYSZKI-DJLDLDEBSA-N
5-(2-chloroethyl)deoxyuridine
A901130
DTXSID501034152

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Against HSV-1 encephalitis, CEDU exerted a significant protective effect at a dosage of 50 mg/kg per day when administered intraperitoneally."( Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.
De Clercq, E; Rosenwirth, B, 1985)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID132944Mean duration of lesions in HSV-1 infected mice, after administration of 0.1 % of compound intracutaneously1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID122202Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered through oral route after 72 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID130018Cumulative lesions in HSV-1 infected mice, after administration of 0.1 % of compound intracutaneously1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID217419Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID156701Antiviral activity against HSV-2 (G) in Primary Rabbit Kidney (PRK) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID130019Cumulative lesions in HSV-1 infected mice, after administration of 0.3 % of compound intracutaneously1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120300In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 100 mg/kg per day; NT=Not tested1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID87983Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-1(thymidine kinase deficient) in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120303In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 25 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID88118Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-2 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID132945Mean duration of lesions in HSV-1 infected mice, after administration of 0.3 % of compound intracutaneously1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120305In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 5 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID87847Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus-1 (Brand) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120302In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 2.5 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID87982Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-1 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID217888Antiviral activity against HSV-1 (Brand) in Vero cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID122195Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered Intraperitoneally after 24 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID167149Minimum cytotoxic concentration of compound causing toxic effects on uninfected cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120288In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 1 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID86209Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87478Tested for in vitro anti-HSV-1 activity; active1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID86208Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID81757Minimum toxic effect against HEp-2 cells.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID87999Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87970Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87971Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by herpes simplex virus (HSV)-1 (K979) in vero cells.1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120304In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 50 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID120291In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 50 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID122198Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered Intraperitoneally after 72 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID84961Minimum inhibitory concentration against HSV-2.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID122199Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered through oral route after 24 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID156700Antiviral activity against HSV-1 (KOS) in Primary Rabbit Kidney (PRK) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87968Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID86207Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID122197Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered Intraperitoneally after 48 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID83146Antiviral activity against VZV (Ellen) in human lung fibroblast (HLF-1) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID217420Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87974Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID120289In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 2.5 mg/kg per day; NT=Not tested1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID120148In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 10 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID122201Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered through oral route after 48 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID167150Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID86215Antiviral activity against HSV-1 (Brand) in human epithelial (Hep-2) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID122200Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered through oral route after 3 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID83893Minimum inhibitory concentration against HSV-1.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID120147In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 100 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID120290In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 25 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID133584Mean survival time in HSV-1 infected mice, after peroral administration of 5 mg/kg of compound1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID133579Mean survival time in HSV-1 infected mice, after intraperitoneal administration of 0.5 mg/kg of compound1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID86216Antiviral activity against HSV-2 (K979) in human epithelial (Hep-2) cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID122196Effect of delayed treatment on mortality of systemically infected mice at 25 mg/kg per day administered Intraperitoneally after 3 hr of start of treatment1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID88114Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID130021Cumulative mortality in percent of HSV-1 infected mice, after intraperitoneal administration of 0.5 mg/kg of compound1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID130025Cumulative mortality in percent of HSV-1 infected mice, after peroral administration of 5 mg/kg of compound1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID217421Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID120292In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered intraperitoneally at a dose 5 mg/kg per day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue.
AID217889Antiviral activity against HSV-2 (K979) in Vero cells1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity.
AID87969Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (56.25)18.7374
1990's3 (18.75)18.2507
2000's2 (12.50)29.6817
2010's1 (6.25)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.61 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		1.97106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phosphonoacetic acid
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.		2.3820monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		1.9610pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		1.9710nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		1.9710carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
thymidine
[no description available]		2.3820pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.3720nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		1.9610nucleobase analogue;
pyrimidines		mutagen
idoxuridine
[no description available]		2.6630organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		3.2260pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
cytidine
[no description available]		3.5110cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		3.5110diazine;
pyrazines		Daphnia magna metabolite
deoxyuridine
[no description available]		5.16150pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.3820beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
ribavirin
Rebetron: Rebetron is tradename		3.51101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
foscarnet sodium
trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		1.9610one-carbon compound;
organic sodium salt		antiviral drug
fialuridine
[no description available]		1.9710
edoxudin
[no description available]		2.3720pyrimidine 2'-deoxyribonucleoside
clevudine
[no description available]		1.9710
5-ethyluracil
5-ethyluracil: antagonist of dihydrouracil dehydrogenase (NADP)		1.9610
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		1.9710divalent inorganic anion;
phosphite ion
n(4)-hydroxycytidine
N(4)-hydroxycytidine : A nucleoside analogue that is cytidine which carries a hydroxy group at the N(4)-positon. It has broad-spectrum antiviral activity against influenza, SARS-CoV , SARS-CoV-2 and MERS-CoV.		3.5110ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral agent;
drug metabolite;
human xenobiotic metabolite
brivudine
brivudine: anti-herpes agent		3.4780
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9710L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
favipiravir
favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.		3.5110hydroxypyrazine;
organofluorine compound;
primary carboxamide		anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
5-(2-bromovinyl)uracil
5-(2-bromovinyl)uracil: RN given refers to (E)-isomer		1.9610
5-(2-iodovinyl)-2'-deoxyuridine
[no description available]		1.9710
arabinofuranosyluracil
Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.		1.9710
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		3.22602-aminopurines;
oxopurine		antimetabolite;
antiviral drug
molnupiravir
molnupiravir: prodrug that’s metabolized into N4-hydroxycytidine (NHC), a ribonucleoside analog. molnupiravir : A nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19.		3.5110isopropyl ester;
ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral drug;
prodrug
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9710
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710
Herpes Simplex Virus Infection
[description not available]		03.0650
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		08.0650
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0210
Herpes Simplex Keratitis
[description not available]		01.9710
Keratitis, Herpetic
A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (KERATITIS, DENDRITIC). (Dictionary of Visual Science, 3d ed)		01.9710
Experimental Neoplasms
[description not available]		01.9610
Furrow Keratitis
[description not available]		01.9610
Iritis
Inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris.		01.9610
chemdatabank.com